Gland Pharma Ltd Share Price

Q: What is the share price of Gland Pharma Ltd today?

Gland Pharma Ltd share price as on 22 Jan 2025 is ₹1645

Pharmaceuticals - Indian - Formulations

NSE: GLAND Small Cap ISIN: INE068V01023

As on 22 January 2025 at 14:59 IST

₹1,645

-14.20

(-0.86%)

Sell Buy

About Gland Pharma Ltd

Gland Pharma Ltd is a leading pharmaceutical company producing complex generic injectables. The company provides high-quality injectable products for various therapeutic areas, including oncology, ophthalmology, and critical care. It operates in the pharmaceutical sector. The company was founded in 1978 in Hyderabad, India, making it decades old. Gland Pharma Ltd headquarters is in Hyderabad, Telangana, India. Gland Pharma’s main products include a wide range of injectables such as liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. The company also focuses on complex injectables, including peptides, suspensions, and hormonal products. Read More...

Over 1 Month

-5.98%

Over 6 Months

-16.82%

Over 1 Year

-11.99%

Over 3 Years

-53.50%

Gland Pharma Ltd Summary

Close ₹ 1,645

Open ₹ 1,659.75

High ₹ 1,665.95

Low ₹ 1,627.50

Volume 59,366

Net Turnover (in ₹) ₹ 17,77,70,446.45

52Wk High ₹ 2,220.95

52Wk Low ₹ 1,585.70

52Wk High / Low

1,585.70

2,220.95

Gland Pharma Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 27,335.61

EPS (TTM) 66.94

Book Value (BV) 556.82

Div. Yield 1.21 %

P/E (TTM) 24.78

Price/Book Value 2.98

Delivery % 58.06 %

Face Value 1

Key Ratios

PE Ratio 29.08

PB Ratio 3.37

EV to Sales 6.90

PEG Ratio 0.84

ROA 11.57

ROE 12.31

Debt-Equity -

Net Profit Margin 25.04

Operating Profit Margin 37.80

Gland Pharma Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	5,834.96	3,865.06	4,624.65	3,597.65	2,772.41
Total Expenses	4,702.41	2,754.02	3,006.09	2,262.84	1,779.54
Profit Before Tax	1,132.54	1,054.58	1,618.55	1,334.81	992.87
Profit After Tax	772.46	781.04	1,211.66	996.96	772.86
Operating Profit after Depreciation	1,158.74	1,118.49	1,623.79	1,338.22	1,000.05

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	3,946.75	1,570.55	1,512.19	954.23	968.10
Total Non Current Assets	5,016.09	1,876.73	1,981.54	1,372.44	1,239.75
Total Current Assets	5,645.15	6,900.81	5,852.08	5,123.64	2,846.29
TOTAL ASSETS	10,661.25	8,777.53	7,833.62	6,496.08	4,086.04
Total Shareholder's Fund	8,723.84	7,958.72	7,157.62	5,903.24	3,646.24

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	996.80	363.97	790.77	604.93	700.94
Net Cash used in Investing Activities	-1,749.19	1,211.19	-999.31	-1,520.42	-760.97
Net Cash used in Financing Activities	-799.42	14.92	34.90	1,238.46	-6.87

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	4,334.09	3,856.99	4,624.65	3,597.65	2,772.41
Total Expenses	2,928.60	2,752.13	3,005.61	2,262.80	1,779.54
Profit Before Tax	1,405.50	1,048.40	1,619.04	1,334.85	992.87
Profit After Tax	1,043.33	775.83	1,212.15	997	772.86
Operating Profit after Depreciation	1,413.34	1,112.28	1,624.28	1,338.26	1,000.05

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	1,693.73	1,570.55	1,512.19	954.23	968.10
Total Non Current Assets	4,969.76	1,884.84	1,989.70	1,372.99	1,239.75
Total Current Assets	4,571.32	6,888.34	5,844.44	5,123.07	2,846.29
TOTAL ASSETS	9,541.09	8,773.18	7,834.14	6,496.06	4,086.04
Total Shareholder's Fund	8,995.29	7,953.30	7,158.23	5,903.28	3,646.24

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	1,135.97	367.89	791.29	604.93	700.94
Net Cash used in Investing Activities	-2,917.58	1,211.22	-1,006.92	-1,520.97	-760.97
Net Cash used in Financing Activities	-7.40	14.92	34.90	1,238.46	-6.87

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	1,405.83	1,401.71	1,537.45	1,545.16	1,373.42
Total Expenses	1,108.77	1,137.32	1,178.80	1,188.77	1,049.35
Profit Before Tax	256.78	218.24	298.23	283.16	289.88
Profit After Tax	163.53	143.76	192.42	191.86	194.08
Operating Profit after Depreciation	356.72	315.82	400.80	393.78	377.23

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	1,062.99	1,012.02	1,174.83	1,097.86	1,010.67
Total Expenses	699.19	718.47	742	728.37	663.56
Profit Before Tax	379.81	300.31	432.70	371.75	347.07
Profit After Tax	281.71	222.92	321.41	276.81	257.53
Operating Profit after Depreciation	421.60	342.04	479.79	412.88	388.22

Gland Pharma Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,641.10

S2 1,623

S3 1,595

Pivot 1,669.10

R1 1,687.20

R2 1,715.20

R3 1,733.30

Moving Average

20 SMA 1,773.19

50 SMA 1,771.12

100 SMA 1,768.90

200 SMA 1,818.80

Gland Pharma Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Gland Pharma Ltd

₹20/Share

Announcement Date 16 Aug 2024

Record Date 16 Aug 2024

Div Yield 2000%

Gland Pharma Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Gland Pharma Ltd	₹1,658.90	₹27,330.66
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Gland Pharma Ltd News

Gland Pharma gets EIR from USFDA for Pashamylaram facility

Gland Pharma announced that it has received an establishment inspection report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Pashamylaram facility at Hyderabad.

18 Jan 2025, 10:50 am

Gland Pharma Ltd up for third straight session

Gland Pharma Ltd is quoting at Rs 1699.55, up 1.41% on the day as on 12:49 IST on the NSE. The stock is down 12.85% in last one year as compared to a 8.15% jump in NIFTY and a 26.91% jump in the Nifty Pharma index.

17 Jan 2025, 01:05 pm

Gland Pharma to announce Quarterly Result

On 3 February 2025

17 Jan 2025, 11:59 am

Gland Pharma gets EIR from USFDA for Dundigal facility

Gland Pharma informed that it has received establishment inspection report (EIR) from the US drug regulator for its Dundigal facility in Hyderabad, indicating closure of the inspection.

16 Jan 2025, 01:00 pm

Gland Pharma Ltd eases for fifth straight session

Gland Pharma Ltd is quoting at Rs 1785, down 2.46% on the day as on 13:19 IST on the NSE. The stock jumped 17.04% in last one year as compared to a 8.66% rally in NIFTY and a 29.08% spurt in the Nifty Pharma index.

10 Jan 2025, 01:35 pm

Gland Pharma Ltd Stock Analysis

Annual revenue for Gland Pharma Ltd increased by 12.37% to ₹4,334.09 crore in FY 2024 from ₹3,856.99 crore in FY 2023.
Annual Net Profit for Gland Pharma Ltd increased by 34.48% to ₹1,043.33 crore in FY 2024 from ₹775.83 crore in FY 2023.
Promoter Shareholding in Gland Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 51.83% in September 2024 to 51.83% in December 2024.
Gland Pharma Ltd delivered a 1-year return of -11.99% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Gland Pharma Ltd share price moved down by 0.86% from its previous close of INR ₹1,659.20. The latest Gland Pharma Ltd share price is INR ₹1,645.
Gland Pharma Ltd share price today has been at a low of 1,627.50 and a high of 1,665.95. Over the past 52 weeks, the Gland Pharma Ltd share price has seen a low of 1,585.70 and a high of 2,220.95.

About Gland Pharma Ltd

Gland Pharma Ltd is a leading pharmaceutical company producing complex generic injectables. The company provides high-quality injectable products across various therapeutic areas. These include oncology, ophthalmology, and critical care. Gland Pharma primarily operates under a business-to-business (B2B) model. It supplies its products to global markets.

Gland Pharma operates in the pharmaceutical sector. It has established itself as a significant player in the industry. The company was founded in 1978 making it decades old. It is now one of the largest and fastest-growing generic injectables companies with a global footprint.

Gland Pharma Ltd's headquarters is in Hyderabad, Telangana, India. The promoters of the company include Fosun Pharma Industrial Pte. Ltd with a significant 51.83% stake in the company. A team of professional managerial promoters manages the operations of the company. These include-

Yiu Kwan Stanley Lau
Srinivas Sadu
Yao Fang
Jia Ai (Allen) Zhang
Qiyu Chen

Gland Pharma’s main products include a wide range of injectables. These consist of liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. The company also focuses on complex injectables. These include peptides, long-acting injectables, suspensions, and hormonal products. These products are essential for various medical treatments. They are widely used in hospitals and healthcare facilities worldwide.

While Gland Pharma is a significant player in the generic injectables sector, it is not the largest in terms of market share. It also falls short in market capitalization. However, it holds a strong position in its niche market. This is particularly true for its manufacturing of complex injectables. This leadership is a testament to the company’s expertise and dedication to quality and innovation. The registered office of Gland Pharma Ltd is in Hyderabad, Telangana, and the registrar's office is in Mumbai, Maharashtra.

Impact of Gland Pharma Limited

Gland Pharma Ltd has made a significant impact on the pharmaceutical industry. This is especially true in the field of generic injectables. Established in 1978, the company has become one of the largest manufacturers of complex injectables. It serves global markets. The importance of Gland Pharma is evident in its contributions to healthcare and economic growth. It also plays a significant role in innovation.

One of the primary impacts of Gland Pharma is its role in improving healthcare outcomes. The company’s high-quality injectable products are essential for treating various medical conditions. These include cancer, infections, and chronic diseases. These products are used in hospitals and healthcare facilities worldwide. They ensure that patients receive adequate and reliable treatments. Gland Pharma’s commitment to quality and safety ensures its products meet stringent regulatory standards. This gives healthcare professionals the confidence to use them in critical care settings.

Gland Pharma’s impact extends to the global pharmaceutical supply chain. The company operates under a business-to-business (B2B) model. It supplies its products to pharmaceutical companies and healthcare providers worldwide. This model allows Gland Pharma to reach various markets. These include the United States, Europe, Canada, Australia, and India.

The company’s focus on complex injectables has positioned it as a leader in the pharmaceutical industry. Gland Pharma specializes in producing a wide range of injectable products. These include liquid vials, lyophilized vials, pre-filled syringes, ampoules, and bags. These products are essential for various therapeutic areas. These include oncology, ophthalmology, and critical care.

Gland Pharma’s impact is also evident in its contributions to economic growth. The company provides employment opportunities to thousands of people. This supports livelihoods and contributes to economic development. Gland Pharma’s operations have a positive ripple effect on the communities where it operates, fostering economic growth and stability.

Innovation is a critical component of Gland Pharma’s impact. The company invests heavily in research and development to create advanced injectable products. These products are designed to meet the market's evolving needs. Gland Pharma’s focus on innovation ensures that it remains competitive and continues to offer solutions that enhance the performance and efficiency of its clients. The company’s R&D efforts focus on developing new formulations. They also aim to improve manufacturing processes. The company focuses on creating advanced solutions that cater to diverse applications.

Gland Pharma’s commitment to sustainability is another important aspect of its impact. The company recognizes the importance of environmental responsibility and is committed to reducing its environmental footprint. Gland Pharma focuses on developing eco-friendly products and implementing sustainable manufacturing practices. The company aims to minimize waste, reduce energy consumption, and use environmentally friendly materials.

The company’s strong leadership and management team have been instrumental in its success. Gland Pharma’s management team is committed to maintaining its reputation for quality and innovation, ensuring its continued success in the market.

Gland Pharma also engages in various corporate social responsibility initiatives. These initiatives aim to improve community health, education, and well-being. The company’s initiatives include supporting healthcare facilities, promoting environmental sustainability, and providing student scholarships. Gland Pharma’s focus on social responsibility reflects its belief that businesses have a role in creating a better world.